Compare AbbVie Inc (ABBV) vs Nebius Group NV (NBIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Nebius Group NV — how do they compare? AbbVie Inc trades at $253.47 (market cap $449.91B), while Nebius Group NV trades at $204.8 (market cap $49.56B). The key difference: AbbVie Inc is far larger — about 9.1× Nebius Group NV's market cap, and AbbVie Inc pays a 2.72% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| ABBV | NBIS | |
|---|---|---|
Market Cap | $449.91B | $49.56B |
Sector | Health | Technology |
52-Week High | $261.07 | $286.69 |
52-Week Low | $184.85 | $44.30 |
Enterprise Value | $513.38B | $49.76B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
NBIS trades at $213.02, down 1.21% with bearish technical signals despite strong analyst support. The stock shows premium valuations (P/E 82.25, P/S 64.41) but impressive profitability (93.09% net margin) and robust revenue growth projections from $530M to $878M. Recent volatility stems from Meta's potential cloud competition, though news highlights Nebius's AI infrastructure strength and institutional buying interest.
Outlook remains positive with 87.5% analyst buy ratings and $233.13 consensus target, but high valuation and competitive risks from tech giants temper near-term upside. Cash flow trends show aggressive expansion funding, while earnings beats/misses reflect execution volatility in a high-growth sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
